Utilidad del estudio del ganglio centinela en carcinoma ductal in situ diagnosticado mediante biopsia con sistema de corte por vacío

Acosta-Marín, Víctor; Acosta-Freites, Víctor; Ramírez, Alfonso; Pérez-Fuentes, Jorge; Marín, Carmen; Contreras, R. F. Garcia; Ravelo, Ricardo; Acosta-Marín, Marthelena; Longobardi, Itala; Vargas, Fanny

doi:10.1016/j.senol.2017.01.001

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found differences with the experience by Heymans et al who reported 3.1% positivity of the sentinel node, probably due to the fact that they performed SLNB only in 66.7% of patients diagnosed with DCIS [9]. And in a Venezuelan experience, where they did not find positivity for SLNB in any patient, despite having a total of 64 patients with a diagnosis of DCIS and a sentinel node identification rate of 95.3%; the study population had the infiltrating component underestimated because they used a vacuum cutting system to diagnose the primary tumor [19]. However, it must be clarified that these values are within the ranges reported in the literature, which range between 1% and 15%.…”

Section: Discussionmentioning

confidence: 93%

When is Sentinel Lymph Node Biopsy Useful in Ductal Carcinoma In Situ? The Experience at a Latin American Cancer Center

Casas

Muñoz

Gómez

et al. 2021

Cureus

View full text Add to dashboard Cite

IntroductionDuctal carcinoma in situ (DCIS) accounts for 15% of breast cancers. Surgery is the main treatment, and the use of sentinel node biopsy (SLNB) is restricted to patients at risk of infiltration, which is estimated to be around 26%. Materials and methodsAimed at evaluating the benefit of SLNB in patients with DCIS at the Breast and Soft Tissue Functional Unit of the National Cancer Institute (INC for its initials in Spanish), a descriptive observational study of a retrospective cases series was conducted between August 1, 2013, and September 30, 2018. ResultsA total of 40 patients with a median age of 57 years were included in the study; 62.5% of them underwent mastectomy with SLNB, and the remaining 37.5% underwent conservative surgery with SLNB. 100% of sentinel nodes were identified, by using lymphoscintigraphy in 95%. Sentinel node was positive in four patients (10%), three of whom had infiltration in the surgical specimen reported. With a follow-up of 49 months, only one patient had a local relapse. None of the patients had axillary or distant recurrence. ConclusionsSLNB in DCIS should be limited to patients with risk factors for infiltration (tumor size greater than 3 cm, comedo-type histology, and high-grade DCIS), and patients with an indication for mastectomy. Its percentage of complications is low, and a high identification percentage in surgical groups with adequate training.

show abstract

Section: Discussionmentioning

confidence: 93%